Abstract：Objective：To study the mechanism of Guanxinning tablets，Chinese patent medicines，for heart failure(HF) with the methods of network pharmacology and molecular docking. Methods：The potential targets of the active components and medicine components of Chinese medicine in Guanxinning tablets were obtained by TCMSP database. HF- related disease targets were searched through Therapeutic Target Database(TTD) and Drugbank database； the intersection genes were obtained after rectifying the medicine targets and disease targets by Uniprot database，and the “component-targetdisease” network of Guanxinning tablets for HF was obtained. The PPI analysis，GO enrichment analysis and KEGG signaling pathway enrichment analysis were performed on the intersection genes using STRING database and DAVID database. Finally， the molecular docking verification was performed on the key active components and targets of Guanxinning tabletsby software，such as AutoDock Vina，ChemBio3D Ultra and PyMOL. Results：A total of 33 active components of medicine and 92 medicine targets in Guanxinning tablets were obtained. A total of 140 HF-related disease targets were obtained from TTD and Drugbank database，and 16 medicine- disease intersection genes were finally obtained. It was predicted that the main components in Guanxinning tablets，such as tanshinoneⅡA，dihydrodantolactone，4-methylenedantoinone，2-isopropyl- 8- methyl phenanthroline- 3，4- diketone and cryptotanshinone， act on 16 HF target genes， such as NR3C1， PPARG， MMPs，CHRM2 and DRD2，and exert therapeutic effects through some signaling pathways，including neuroactive ligandreceptor interaction signaling pathway， cGMP- PKG signaling pathway， cAMP signaling pathway， Ca2 + signaling pathway and tumor-associated signaling way. It was verified by molecular docking that the binding activity of tanshinoneⅡA，the main component of Guanxinning tablets， and NR3C1， the main target gene， with high binding degree and stable conception. Conclusion：The characteristics of multi- component，multi- target and multi- pathway of Guanxinning tablets for HF were verified by network pharmacology. It may affect the ventricular remodeling and regulate the myocardial contractility to exert its therapeutic effect by adjusting and controlling the transcription of DNA/RNA and regulating the body fluid-hormonal-related signal transduction and contraction of smooth muscle.